Default Category
-
Rosslyn Resource: Monetization and Sales Strategy
Dolan, Robert J.; Yong, SunruCase HBS-918509-EMarketingRosslyn Resource identifies exploration targets (potential mineral deposits) in the mining industry and advances them until the project can be monetized, usually through sale to a larger mining company, in return for an upfront fee and a royalty on future revenues. Rosslyn has invested heavily in developing proprietary, innovative equipment and geological data sets that would make exploration cheaper and faster. Rosslyn must decide what to do wi...Starting at €8.20
-
Hitachi Rail Limited (B)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721365-EStrategyDescribes the strategy and organisation changes made by British executive, Alistair Domer, after he is made head of Hitachi Rail's global business. The company acquires an Italian company, continues to win contracts in the UK, but struggles to bring its gStarting at €5.74
-
Takeda Pharmaceutical Company Limited (B)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721374-EStrategyThis case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challengeStarting at €5.74
-
Rosslyn Resource: Monetization and Sales Strategy, Teaching Note
Dolan, Robert J.; Yong, SunruTeaching Note HBS-918510-EMarketingTeaching note for case 918509.Starting at €0.00
-
Hitachi Rail Limited (A)
Collis, David J.; Kanno, Akiko; Sato, NobuoCase HBS-721364-EStrategyHitachi must decide whether to make a British executive, who has successfully built its European rail business from scratch, head of its global rail division even though the bulk of revenues for the unit still come from Japan. The case describes, the histStarting at €8.20
-
Takeda Pharmaceutical Company Limited (A)
Collis, David J.; Sato, Nobuo; Kanno, AkikoCase HBS-721373-EStrategyThis case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition woStarting at €8.20